Trends in laboratory testing for diabetes in Ontario, Canada 1995-2005: A population-based study

BMC Health Services Research

Volumn 9, Issue , 2009, Pages

  Wilson, Sarah E ^a,b   Lipscombe, Lorraine L ^a,c,d   Rosella, Laura C ^a,b   Manuel, Douglas G ^a,b  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMBULATORY CARE; ARTICLE; CANADA; DATA BASE; DIABETES MELLITUS; DIAGNOSTIC TEST; HUMAN; LABORATORY; MIDDLE AGED; STATISTICS;

AMBULATORY CARE; DATABASES AS TOPIC; DIABETES MELLITUS; DIAGNOSTIC TESTS, ROUTINE; HUMANS; LABORATORIES; MIDDLE AGED; ONTARIO;

EID: 62749126704     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-9-41     Document Type: Article

References (31)

1. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. H King RE Aubert WH Herman, Diabetes Care 1998 21 1414 31 10.2337/diacare.21.9.1414 9727886
2. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. S Wild G Roglic A Green R Sicree H King, Diabetes Care 2004 27 1047 53 10.2337/diacare.27.5.1047 15111519
3. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. L Lipscombe JE Hux, Lancet 2007 369 750 756 10.1016/S0140-6736(07)60361-4 17336651
4. Prevalence and trends in obesity among US adults, 1999-2000. KM Flegal MD Carroll CL Ogden CL Johnson, JAMA 2002 288 1723 1727 10.1001/jama.288.14.1723 12365955
5. Prevalence of overweight and obesity in the United States, 1999-2004. CL Ogden MD Carroll LR Curtin MA McDowell CJ Tabak KM Flegal, JAMA 2006 295 1549 1555 10.1001/jama.295.13.1549 16595758
6. Prevalence of class I, II and III obesity in Canada. PT Katzmarzyk C Mason, CMAJ 2006 174 156 157 16415457
7. Prevalence of obesity in Great Britain. KL Rennie SA Jebb, Obes Rev 2005 6 11 12 10.1111/j.1467-789X.2005.00164.x 15655034
8. Overweight and obesity in Australia: the 1999-2000 Australian diabetes, obesity and lifestyle study (AusDiab). AJ Cameron TA Welborn PZ Zimmet DW Dunstan N Owen J Salmon M Dalton D Jolley J Shaw, Med J Aust 2003 178 427 432 12720507
9. Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the US Population. National Health and Nutrition Examination Survey 1999-2002. CC Cowie KF Rust DD Byrd-Holt MS Eberhardt KM Flegal MM Engelgau SH Saydah DE Williams LS Geiss EW Gregg, Diabetes Care 2006 29 1263 1268 10.2337/dc06-0062 16732006
10. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. MI Harris KM Flegal CC Cowie MS Eberhardt DE Goldstein RR Little HM Wiedmeyer DD Byrd-Holt, Diabetes Care 1998 21 518 24 10.2337/diacare.21.4.518 9571335
11. Undiagnosed diabetes: Does it matter? TK Young CA Mustard, CMAJ 2001 164 24 28 11202663
12. Diabetes screening in Canada (DIASCAN) Study. LA Leiter A Barr A Bélanger S Lubin SA Ross HD Tildesley N Fontaine, Diabetes Care 2001 24 1038 1043 10.2337/diacare.24.6.1038 11375367
13. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. MI Harris R Klein TA Welborn MW Knuiman, Diabetes Care 1992 15 815 819 10.2337/diacare.15.7.815 1516497
14. 1998 clinical practice guidelines for the management of diabetes in Canada. S Meltzer L Lawrence D Daneman HC Gerstein D Lau S Ludwig J-F Yale B Zinman D Lillie Steering and Expert Committees, CMAJ 1998 Suppl S1 29
15. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Can J Diabetes 2003 27 S10 S13
16. Clinical practice guidelines for treatment of diabetes mellitus. Expert Committee of the Canadian Diabetes Advisory Board, CMAJ 1992 147 697 712 1521215
17. Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. DS Feig VA Palda L Lipscombe the Canadian Task Force on Preventive Health Care, CMAJ 2005 172 177 80 15655234
18. Diabetes in Ontario. Determination of prevalence and incidence using a validated administrative data algorithm. JE Hux F Ivis V Flintoft A Bica, Diabetes Care 2002 25 512 516 10.2337/diacare.25.3.512 11874939
19. Ontario Ministry of Health and Long Term Care, Schedule of Laboratory Fees, Preamble http://www.health.gov.on.ca/english/providers/program/ohip/sob/ lab/lab-mn.html Accessed March 28, 2007
20. Performance measures from 10 years of breast screening in the Ontario Breast Screening Program, 1990/91 to 2000. AM Chiarelli E Halapy V Nadalin R Shumak F O'Malley V Mai, Eur J Cancer Prev 2006 15 34 42 10.1097/01.cej. 0000195713.02567.36 16374227
21. Public Health Agency of Canada, Organized breast cancer screening programs in Canada: Report on Program Performance in 2001 and 2002 http://www.phac-aspc.gc.ca/publicat/obcsp-podcs01/pdf/Breast-En-2001-2002.pdf (accessed June 7, 2007)
22. Inadequacy of cervical cancer screening among urban recent immigrants: A population-based study of physician and laboratory claims in Toronto, Canada. A Lofters RH Glazier MM Agha MI Creatore R Moineddin, Prev Med 2007 44 536 542 10.1016/j.ypmed.2007.02.019 17467782
23. Comparison of papanicolaou (Pap) test rates across Ontario and factors associated with cervical screening. G Fehringer R Howlett M Cotterchio N Klar V Majpruz-Moat V Mai, Can J Public Health 2005 96 140 4 15850036
24. The impact of new guidelines for glucose tolerance testing on clinical practice and laboratory services. AW Lyon ET Larsen AL Edwards, CMAJ 2004 171 1067 1069 15505270
25. Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study. PGH Janssen KJ Gorter RP Stolk GEHM Rutten, Family Practice 2007 24 555 561 10.1093/fampra/cmm052 17962235
26. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group, BMJ 1998 317 371 375 9694750
27. Report of the expert committee on the diagnosis and classification of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 1997 20 1183 1197 9203460
28. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. E Barrett-Connor A Ferrara, Diabetes Care 1998 21 1236 1239 10.2337/diacare.21.8.1236 9702426
29. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 2003 26 3160 3167 10.2337/diacare.26.11.3160 14578255
30. HbA1c as a screening tool for detection of Type 2 diabetes: a systematic review. CM Bennett M Guo SC Dharmage, Diabet Med 2007 24 333 343 10.1111/j.1464-5491.2007.02106.x 17367307
31. Diagnostic value of glycated haemoglobin (HbA1c) for the early detection of diabetes in high-risk subjects. KS Kim SK Kim YK Lee SW Park YW Cho, Diabet Med 2008 25 997 1000 10.1111/j.1464-5491.2008.02489.x 18959616